Trial Number

559-25

Condition

Lung Cancer

Participant Age Range

18 years and older

Participant Gender

Any

Enrolling Participants

Yes

Overview

“A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)”

The purpose of eVOLVE-Lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1L treatment in participants with mNSCLC in PD-L1 TC < 1% and PD-L1 TC < 50%.

Provider

Cancer Institute

Amol H Rao, MD

Hematology-Oncology, Hematology/Oncology
Fountain Valley
View Profile

Location

Orange Coast Medical Center

18111 Brookhurst Street
Fountain Valley
714-378-7000
Location Details

Related Clinical Trials

Click on the category you are interested in.

Cancer Care Lung & Respiratory Care Orange Coast Medical Center
Name
Enter Trial number from the area just below the marquee.
How would you prefer to be contacted?
How did you hear about us?
This registration is for:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.